Podofilox Gel (Condylox Gel)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Podofilox Gel (Condylox Gel)

Condylox® Gel 0.5%
(podofilox) Gel

DRUG DESCRIPTION

Podofilox is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae ( e.g. species of Juniperus and Podophyllum). Condylox Gel (podofilox gel) 0.5% is formulated for topical administration. Each gram of gel contains 5 mg of podofilox in a buffered alcoholic gel containing alcohol, glycerin, lactic acid, hydroxypropyl cellulose, sodium lactate, and butylated hydroxytoluene.

Podofilox has a molecular weight of 414.4 daltons, and is soluble in alcohol and sparingly soluble in water. Its chemical name is [5R,-(5α, 5aβ, 8aα, 9α]-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl) furo[3',4':6,7]naphtho-[2,3,-d]-1,3-dioxol-6(5aH)-one.

Podofilox has the following structural formula:

Condylox (podofilox) structural formula illustration

What are the possible side effects of podofilox topical (Condylox)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Wash off the medicine and call your doctor at once if you have a serious skin reaction such as severe itching, burning, oozing, bleeding, or skin changes where the medicine is applied.

Less serious side effects may include:

  • mild skin irritation, tenderness, bleeding, dryness, peeling, tingling, scarring, blistering, crusting, or swelling of the skin where the medicine was applied;
  • sleep...

Read All Potential Side Effects and See Pictures of Condylox Gel »

What are the precautions when taking podofilox gel (Condylox Gel)?

Before taking podofilox, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: other skin problems (e.g., skin cancer).

This medication must not be used during pregnancy. Women of child-bearing age should use a reliable form of birth control while using this medication. If you become pregnant or think you may be pregnant, inform your doctor immediately.

It is unknown if this drug passes into breast milk. Consult your doctor before...

Read All Potential Precautions of Condylox Gel »

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

Condylox Gel (podofilox gel) 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS).

Diagnosis

Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and "Bowenoid papulosis" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with Condylox Gel (podofilox gel) 0.5%.

DOSAGE AND ADMINISTRATION

The prescriber should ensure that the patient is fully aware of the correct method of therapy and identify which specific warts should be treated.

Apply twice daily for 3 consecutive days, then discontinue for 4 consecutive days. This one week cycle of treatment may be repeated until there is no visible wart tissue or for a maximum of four cycles. If there is incomplete response after four treatment cycles, discontinue treatment and consider alternative treatment. Safety and effectiveness of more than four treatment cycles has not been established. There is no evidence to suggest that more frequent application will increase efficacy, but additional applications would be expected to increase the rate of local adverse reactions and systemic absorption.

Condylox Gel (podofilox gel) 0.5% should be applied to the warts with the applicator tip or finger. Application on the surrounding normal tissue should be minimized. Treatment should be limited to 10 cm2 or less of wart tissue and to no more than 0.5 g of the gel per day.

Care should be taken to allow the gel to dry before allowing the return of opposing skin surfaces to their normal positions. Patients should be instructed to wash their hands thoroughly before and after each application.

HOW SUPPLIED

Condylox Gel (podofilox gel) 0.5% is supplied as 3.5 g of clear gel in aluminum tubes with an applicator tip. NDC 52544-045-13. Store at controlled room temperature between 15 - 30°C (59 - 86° F). Avoid excessive heat. Do not freeze.

Keep out of reach of children.

Mfd. for: Watson Pharmaceuticals, Inc. Corona, CA 92880 USA by DPT Laboratories, Ltd. San Antonio, TX 78215. Revised: November 2007. FDA rev date: 3/13/1997

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

In clinical trials with Condylox Gel (podofilox gel) 0.5%, the following local adverse reactions were reported during the treatment of anogenital warts. The severity of local adverse reactions were predominantly mild or moderate and did not increase during the treatment period. Severe reactions were most frequent within the first 2 weeks of treatment.

Adverse Reaction Mild Moderate Severe
Inflammation 32.2% 30.4% 9.3%
Burning 37.1% 25.9% 11.5%
Erosion 27.0% 20.8% 8.9%
Pain 23.7% 20.4% 11.5%
Itching 32.2% 16.0% 7.8%
Bleeding 19.2% 3.0% 0.7%

Other local adverse reactions reported included stinging (7%), and erythema (5%); less commonly reported local adverse events included desquamation, scabbing, discoloration, tenderness, dryness, crusting, fissures, soreness, ulceration, swelling/edema, tingling, rash, and blisters.

The most common systemic adverse event reported during the clinical studies was headache (7%).

Read the Condylox Gel (podofilox gel) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

No information provided.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Correct diagnosis of the lesions to be treated is essential. See the Diagnosis subsection of the INDICATIONS AND USAGE section. Condylox Gel (podofilox gel) 0.5% is intended for cutaneous use only. Avoid contact with the eyes. If contact with the eyes occurs, patients should immediately flush the eyes with copious quantities of water and seek medical advice.

Drug Product is Flammable.

Keep Away From Open Flame.

PRECAUTIONS

General

Data are not available on the safe and effective use of this product for treatment of warts occurring on mucous membranes of the genital area (including the urethra, rectum and vagina). The recommended method of application, frequency of application, and duration of usage should not be exceeded (see DOSAGE AND ADMINISTRATION).

Carcinogenesis, Mutagenesis and Impairment of Fertility

An 80-week carcinogenicity study in the mouse was performed using a 0.5% podofilox solution applied dermally at 0.04, 0.2 and 1.0 mg/kg/day. There were no differences between the podofilox treated mice at any dose level and vehicle control in the incidence of neoplasia. Published animal studies, in general, have not shown the drug substance, podofilox, to be carcinogenic.2,3,4,5,6 There are published reports that, in mouse studies, crude podophyllin resin (containing podofilox) applied topically to the cervix produced changes resembling carcinoma in situ7 These changes were reversible at five weeks after cessation of treatment. In one reported experiment, epidermal carcinoma of the vagina and cervix was found in 1 out of 18 mice after 120 applications of podophyllin8 (the drug was applied twice weekly over a 15-month period).

Podofilox was not mutagenic in the Ames plate reverse mutation assay at concentrations up to 5 mg/plate, with and without metabolic activation. No cell transformation related to potential oncogenicity was observed in BALB/3T3 cells after exposure to podofilox at concentrations up to 0.008 µg/mL, without metabolic activation and 12 ug/mL podofilox with metabolic activation. Results from the mouse micronucleus in vivo assay using podofilox 0.5% solution at doses up to 25 mg/kg (75 mg/m2), indicate that podofilox should be considered a potential clastogen (a chemical that induces disruption and breakage of chromosomes).

Daily topical application of 0.5% podofilox solution at doses up to the equivalent of 0.2 mg/kg (1.18 mg/m2, approximately equivalent to the human daily dose) to rats throughout gametogenesis, mating, gestation, parturition and lactation for two generations demonstrated no impairment of fertility.

Pregnancy

Pregnancy Category C: 0.5% podofilox solution was not teratogenic in the rabbit following topical application of up to 0.21 mg/kg (2.85 mg/m2, approximately 2 times the maximum human dose) once daily for 13 days. The scientific literature contains references that

podofilox is embryotoxic in rats when administered intraperitoneally at a dose of 5 mg/kg (29.5 mg/m2, approximately 19 times the recommended maximum human dose.)9 Teratogenicity and embryotoxicity have not been studied with intravaginal application. Many antimitotic drug products are known to be embryotoxic. There are no adequate and well-controlled studies in pregnant women. Condylox Gel (podofilox gel) 0.5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from podofilox, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

REFERENCES

2. Berenblum I. The effect of podophyllotoxin on the skin of the mouse, with reference to carcinogenic, cocarcinogenic, and anticarcinogenic action. J Cancer Inst 11:839-841, 1951.

3. Kaminetzky HA, Swerdlow M. Podophyllin and the mouse cervix: assessment of carcinogenic potential. Am J Obst Gyn 95:486-490, 1965.

4. McGrew EA, Kaminetzky HA. The genesis of experimental cervical epithelial dysplasia. Am J Clin Path 35:538-545, 1961.

5. Roe FJC, Salaman MH. Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.) 1,2 benxanthracene and beta-propiolactone as initiators of skin tumor formation in the mouse. Brit J Cancer, 9:177-203, 1955.

6. Taper HS. Induction of the deficient acid DNAase activity in mouse interfollicular epidermis by croton oil as a possible tumor promoting mechanism. Zeitschrift fur Krebsforschung and Klinisch Onkologie (Cancer Research and Clinical Oncology, Berlin) 90:197-210, 1977.

7. Kaminetzky HA, McGrew EA, Phillips RL. Experimental cervical epithelial dysplasia. J Obst Gyn 14:1-10, 1959.

8. Kaminetzky HA, McGrew EA: Podophyllin and mouse cervix: Effect of long term application. Arch Path 73:481-485, 1962.

9. Thiersch JB. Effect of podophyllin (P) and podophylotoxine (PT.) on the rat litter in utero. Soc Exptl Biol Med Proc. 113:124-127, 1963.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Topically applied podofilox may be absorbed systemically (see CLINICAL PHARMACOLOGY section). Toxicity reported following systemic administration of podofilox in investigational use for cancer treatment included: nausea, vomiting, fever, diarrhea, bone marrow depression, and oral ulcers. Following 5 to 10 daily intravenous doses of 0.5 to 1 mg/kg/day, significant hematological toxicity occurred but was reversible.10 Other toxicities occurred at lower doses. Toxicity reported following systemic administration of podophyllum resin included: nausea, vomiting, fever, diarrhea, peripheral neuropathy, altered mental status, lethargy, coma, tachypnea, respiratory failure, leukocytosis, pancytosis, hematuria, renal failure and seizures.11 Treatment of topical overdosage should include washing the skin free of any remaining drug and symptomatic and supportive therapy.

CONTRAINDICATIONS

Condylox Gel (podofilox gel) 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any components of the formulation.

REFERENCES

10. Savel H.: Clinical experience with intravenous podophyllotoxin. Proc Amer Assoc Cancer Res, 1964; 5: 56.

11. Cassidy DE, Dewry J and Fanning JP: Podophyllum toxicity: A report of a fatal case and a review of the literature. J Toxicol Clinic Toxicol 1982: 19: 35-44.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Mechanism of Action

Treatment of anogenital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown.

Pharmacokinetics

In systemic absorption studies in 52 patients, topical application of 0.05 ml_ of an ethanolic solution containing 0.5% podofilox to external genitalia did not result in detectable serum levels. Applications of 0.1 to 1.5 ml_ resulted in peak serum levels of 1 to 17 ng/mL one to two hours after application. The elimination half-life ranged from 1.0 to 4.5 hours. The drug was not found to accumulate after multiple treatments1.

Clinical Studies

In the first multicenter clinical study in 326 patients with anogenital warts, Condylox Gel (podofilox gel) 0.5% and its vehicle were applied in a double-blind fashion to comparable patient groups. Of the 260 patients with efficacy data, 176 were treated with Condylox Gel (podofilox gel) 0.5%. Patients applied Condylox Gel (podofilox gel) 0.5% twice daily for three consecutive days followed by a 4 day "rest" period.

At the end of 4 weeks, 38.4% of the patients had complete clearing of the wart tissue when treated with Condylox Gel (podofilox gel) 0.5%.

In the second multicenter clinical trial in 108 evaluable patients with anogenital warts, Condylox (podofilox) Topical Solution 0.5% was compared with Condylox Gel (podofilox gel) 0.5% for efficacy. As in the first clinical trial, patients applied Condylox Gel (podofilox gel) 0.5% twice daily for three consecutive days followed by a four day "rest" period.

Similar clearance rates were observed. At the end of 4 weeks, 25.6% of the patients had complete clearing of the wart tissue when treated with Condylox Gel (podofilox gel) 0.5%.

REFERENCES

1. von Krogh G. Podophyllotoxin in serum: Absorption subsequent to three day repeated applications of a 0.5% ethanolic preparation on condylomata acuminata. Sex Trans Disease 1982: 9: 26-33.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

Patients using Condylox Gel (podofilox gel) 0.5% should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not intended to disclose all possible adverse or intended effects.

  1.  This medication should be used only as directed by the health care provider. Patients should be instructed to wash their hands thoroughly before and after each application. It is for external use only. Avoid contact with the eyes.
  2.  Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3.  Patients should report any signs of adverse reactions to the health care provider.
  4.  If no improvement is observed after 4 weeks of treatment, discontinue the medication and consult the health care provider.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

Patients using Condylox Gel (podofilox gel) 0.5% should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not intended to disclose all possible adverse or intended effects.

  1.  This medication should be used only as directed by the health care provider. Patients should be instructed to wash their hands thoroughly before and after each application. It is for external use only. Avoid contact with the eyes.
  2.  Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3.  Patients should report any signs of adverse reactions to the health care provider.
  4.  If no improvement is observed after 4 weeks of treatment, discontinue the medication and consult the health care provider.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Condylox Gel Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

PODOFILOX GEL - TOPICAL

(poe-DOF-il-ox)

COMMON BRAND NAME(S): Condylox

USES: This medication is used on the skin to treat external genital warts.

HOW TO USE: This medication is for topical use only. Apply it on the warts pointed out by your doctor. It is usually applied once in the morning and again in the evening for 3 days followed by a 4 day rest period. If the warts do not go away, then this cycle is repeated up to 4 times. Contact your doctor for other options if the warts do not go away after 4 weeks of treatment.

To apply, use the provided applicator tip or your finger. Apply a small amount of medication to the wart to cover it. Allow the gel to dry. Wash your hands thoroughly afterwards. Be careful with this medication because it can irritate normal skin around the application site.

Do not use large amounts, apply more often or use for a longer period than directed. Your condition will not clear faster, and the chance for side effects may be increased.

Avoid contact with the eyes and mucous membranes. If contact occurs, immediately wash with plenty of water and contact your doctor.

Read the Patient Information Leaflet available from your pharmacist. Consult your doctor or pharmacist if you have any questions.

Disclaimer

Condylox Gel Consumer (continued)

SIDE EFFECTS: Swelling, pain, burning, itching, peeling skin, small sores, or headache may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if this serious side effect occurs: bleeding.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Condylox Gel (podofilox gel) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before taking podofilox, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: other skin problems (e.g., skin cancer).

This medication must not be used during pregnancy. Women of child-bearing age should use a reliable form of birth control while using this medication. If you become pregnant or think you may be pregnant, inform your doctor immediately.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Disclaimer

Condylox Gel Consumer (continued)

DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with them first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.

Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. This medicine may be harmful if swallowed. If accidentally swallowed, you may experience symptoms such as: nausea, vomiting, diarrhea, change in mental status, weakness or fatigue, unusually slowed breathing, and seizures.

NOTES: This medication is prescribed for your current condition only. Do not use it later for another skin problem unless directed by your doctor. A different medication may be necessary in those cases.

Do not share this medication with others.

This medication is not a cure. New warts or return of old warts may occur, especially in the first 3 months after treatment. Follow-up medical visits may be periodically necessary to monitor your progress or check for side effects. Consult your doctor for more details.

Refrain from sexual intercourse on the days you apply this drug. Using condoms may help prevent the spread of genital warts to your partner.

MISSED DOSE: If you miss a dose, apply it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature between 59-86 degrees F (15-30 degrees C) away from heat or open flame. Do not freeze. Replace the cap tightly after use. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised October 2010. Copyright(c) 2010 First Databank, Inc.

Condylox Gel Patient Information Including Side Effects

Brand Names: Condylox

Generic Name: podofilox topical (Pronunciation: poe DOF il lox)

What is podofilox topical (Condylox Gel)?

Podofilox prevents the growth of certain types of cells.

Podofilox topical (for the skin) is used to treat genital warts that appear on the outside of the body, but this medicine is not a cure for genital warts.

Podofilox topical may also be used for other purposes not listed in this medication guide.

What are the possible side effects of podofilox topical (Condylox Gel)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Wash off the medicine and call your doctor at once if you have a serious skin reaction such as severe itching, burning, oozing, bleeding, or skin changes where the medicine is applied.

Less serious side effects may include:

  • mild skin irritation, tenderness, bleeding, dryness, peeling, tingling, scarring, blistering, crusting, or swelling of the skin where the medicine was applied;
  • sleep problems (insomnia);
  • unpleasant skin odor;
  • nausea, vomiting; or
  • pain during sex.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Condylox Gel (podofilox gel) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about podofilox topical (Condylox Gel)?

Do not use this medication on any warts or skin growths that have not been checked by your doctor.

Using more of this medication will not make it work better, and may increase side effects.

Avoid getting this medication in your eyes. If this does happen, rinse with water and call your doctor. Do not place the gel or solution in your rectum, vagina, or urethra. If it does get into any of these areas, rinse with water.

Avoid having unprotected sex. Podofilox is not a cure for genital warts, and it will not protect against sexually transmitted diseases such as chlamydia, gonorrhea, herpes, HIV, syphilis, and trichomoniasis. Talk with your doctor about safe ways to prevent transmission during sex.

Wash your hands before and after applying podofilox topical.

Side Effects Centers

Condylox Gel Patient Information including How Should I Take

What should I discuss with my healthcare provider before using podofilox topical (Condylox Gel)?

You should not use podofilox topical if you are allergic to it.

Do not use this medication on any warts or skin growths that have not been checked by your doctor.

FDA pregnancy category C. It is not known whether podofilox topical will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication..

It is not known whether podofilox topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use podofilox topical (Condylox Gel)?

Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Your healthcare provider may show you how to apply this medicine at home.

Using more of this medication will not make it work better, and may increase side effects.

Wash your hands before applying podofilox topical. Also wash the skin area to be treated, and allow it to dry completely before applying the medicine.

Apply the medication using the cotton applicator provided or with your finger. Apply podofilox only to the wart tissue and avoid getting it on healthy skin. If the genital wart is in a skin fold, spread the skin apart and apply the medicine. Allow the treated skin to dry before releasing the skin fold.

This medication is usually applied in the morning and evening for 3 days in a row, followed by 4 days of not using the medicine. This 7-day treatment cycle should be repeated up to 4 times, or until you can no longer see any signs of wart tissue.

Wash your hands again after applying podofilox topical.

Call your doctor if your symptoms do not improve after 4 treatment cycles.

Podofilox topical is not a cure for genital warts and it may not keep you from spreading this condition to others through vaginal, anal, or oral sex. You may develop new lesions during treatment with podofilox topical. For best results, keep using the medicine for the entire length of time prescribed by your doctor.

Store at room temperature away from moisture and heat. Do not freeze.

This medication is flammable. Do not use it near high heat or open flame, or while you are smoking.

Side Effects Centers

Condylox Gel Patient Information including If I Miss a Dose

What happens if I miss a dose (Condylox Gel)?

Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose (Condylox Gel)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may result if you absorb this medicine through your skin by applying too much of it. Symptoms may include nausea, vomiting, diarrhea, fever, flu symptoms, sores in your mouth and throat, numbness or tingling in your hands or feet, confusion, trouble breathing, or seizure (convulsions).

What should I avoid while using podofilox topical (Condylox Gel)?

Do not have sex on the days you apply podofilox topical.

Avoid getting this medication in your eyes. If this does happen, rinse with water and call your doctor. Do not place the gel or solution in your rectum, vagina, or urethra. If it does get into any of these areas, rinse with water.

Avoid having unprotected sex. Podofilox is not a cure for genital warts, and it will not protect against sexually transmitted diseases such as chlamydia, gonorrhea, herpes, HIV, syphilis, and trichomoniasis. Talk with your doctor about safe ways to prevent transmission during sex.

What other drugs will affect podofilox topical (Condylox Gel)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied podofilox. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about podofilox topical.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 1.05. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com